Publications by authors named "Liliana Tuskova"
Article Synopsis
- Targeting PI3K/AKT/PTEN signalling offers promising therapy options for B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), despite challenges with existing PI3K inhibitors due to toxicity.
- The AKT inhibitor capivasertib, when used with the BCL-2 inhibitor venetoclax, shows significant therapeutic benefits in preclinical DLBCL models, inducing tumor cell death effectively.
- Adding rituximab to this drug combination enhances treatment outcomes, suggesting a potentially effective strategy for managing DLBCL patients who are resistant to standard therapies.
Article Synopsis
- Venetoclax (VEN) shows promising activity against various lymphomas and leukemias, but remissions tend to be short, prompting the need for combination therapies.
- Research found that combining VEN with A1155463, a BCL-XL inhibitor, created a strong synergistic effect and could overcome resistance in certain cell lines, even those lacking BCL2L11/BIM, which is often linked to VEN resistance.
- In vivo studies confirmed the effectiveness of this combination in multiple patient-derived models, and a unique treatment schedule of 4 days on/3 days off minimized side effects, making this a potential innovative approach for treating BCL2+ hematologic malignancies.
The MHC II-EGFP knock-in mouse model enables us to visualize and track MHC-II-expressing cells in vivo by expressing enhanced green fluorescent protein (EGFP) fused to the MHC class II molecule under the MHC II beta chain promoter. Using this model, we can easily identify MHC-II-expressing cells, including dendritic cells, B cells, macrophages, and ILC3s, which play a key role as antigen-presenting cells (APCs) for CD4 T cells. In addition, we can also precisely identify and analyze APC-containing tissues and organs.
View Article and Find Full Text PDFImmunology is a rapidly evolving field of research with sophisticated models and methods. However, detailed data on total immune cell counts and population distributions remain surprisingly scarce. Nevertheless, recently established quantitative approaches could help us understand the overall complexity of the immune system.
View Article and Find Full Text PDF